The effect of Goreisan to prevent the recurrence of chronic subdural hematoma

The effect of Goreisan to prevent the recurrence of chronic subdural hematoma - The effect of Goreisan to prevent the recurrence of chronic subdural hematoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010006

Enrollment

224

Registered

2013-02-20

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic subdural hematoma

Interventions

1. Patients assigned to Goreisan group are started on Goreisan, 7.5g TID, for 3 months after surgery. 2. Patients assigned to No medicine group are simply followed-up on a out-patient basis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with symptomatic chronic subdural hematoma who need surgical treatment

Exclusion criteria

Exclusion criteria: 1. Patients under the age of 18 2. Patients already treated surgically before 3. Patients with possibilities to develop drug side effect

Design outcomes

Primary

Measure	Time frame
Postoperative symptomatic reaccumulation of hematoma.	—

Countries

Japan

Contacts

Public ContactNaoaki Fujisawa

Saitama Medical School/Center Department of Neurosurgery

naoaki@saitama-med.ac.jp049-228-3671

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026